Stock listing

NASDAQ:RNAZ TransCode Therapeutics, Inc. Stock

Home listing (NASDAQ) of TransCode Therapeutics, Inc.

Follow TransCode Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:RNAZ

$1.16 USD -0.19 (-13.8%)

Close on Nov 20, 2026

Past year -86.4% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$1.01 – $1.35 USDNov 20, 2026
Volume
60,672 sharesNov 20, 2026
Market cap
$20.07M USDAt the close on Nov 20, 2026 · price × 17.30M shares outstanding
52-week range
$1.01 – $12.60 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$100,057 USDMedian day 29,017 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
TransCode Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:RNAZ · Home$1.16 USD-0.185 (-13.8%)60,672$1.35$1.35$1.01$1.345Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:RNAZ · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$1.16-0.185-13.8%$1.35$1.35$1.0160,672
$1.345-0.065-4.6%$1.39$1.40$1.2918,083
$1.41+0.06+4.4%$1.46$1.527$1.2836,661
$1.35+0.03+2.3%$1.34$1.47$1.2950,315
$1.32-0.07-5.1%$1.43$1.45$1.3020,847
$1.39-0.01-0.7%$1.36$1.47$1.3513,915
$1.40+0.05+3.7%$1.33$1.44$1.3311,992
$1.35-0.19-12.3%$1.51$1.55$1.3324,029
$1.54+0.05+3.4%$1.57$1.59$1.5016,155
$1.49-0.02-1.3%$1.53$1.56$1.4512,777
$1.51-0.09-5.6%$1.63$1.67$1.47521,850
$1.60+0.03+1.9%$1.61$1.72$1.577,097
$1.57-0.06-3.7%$1.60$1.65$1.5029,550
$1.630.000.0%$1.69$1.69$1.6116,519
$1.63-0.10-5.8%$1.73$1.785$1.6216,185
$1.73-0.01-0.6%$1.837$1.91$1.7339,291
$1.74+0.07+4.2%$1.61$1.78$1.6118,493
$1.67-0.036-2.1%$1.71$1.77$1.657,502
$1.706-0.065-3.6%$1.78$1.78$1.7054,290
$1.77+0.055+3.2%$1.65$1.84$1.6532,683
$1.715+0.055+3.3%$1.62$1.80$1.6227,965
$1.66-0.02-1.2%$1.69$1.81$1.6516,753
$1.68-0.02-1.2%$1.71$1.75$1.60320,230
$1.700.000.0%$1.70$1.84$1.6629,305
$1.70-0.10-5.6%$1.83$1.864$1.69529,017
$1.80+0.07+4.0%$1.79$1.90$1.7135,314
$1.73+0.05+3.0%$1.74$1.82$1.6743,235
$1.68+0.05+3.1%$1.67$1.78$1.66854,452
$1.63-0.23-12.4%$1.91$1.91$1.6331,932
$1.86+0.15+8.8%$1.78$1.95$1.7484,076
$1.71-0.05-2.8%$1.80$1.80$1.67527,836
$1.76-0.02-1.1%$1.78$1.79$1.6729,763
$1.78+0.02+1.1%$1.77$1.815$1.7147,336
$1.76+0.19+12.1%$1.65$1.87$1.5765,725
$1.57+0.025+1.6%$1.58$1.66$1.54515,503
$1.545-0.135-8.0%$1.673$1.74$1.5216,712
$1.68+0.05+3.1%$1.748$1.748$1.646,733
$1.63-0.08-4.7%$1.73$1.81$1.6011,006
$1.71+0.02+1.2%$1.71$1.79$1.6340,680
$1.69+0.04+2.4%$1.60$1.70$1.6014,760
$1.65-0.03-1.8%$1.62$1.74$1.6228,656
$1.68-0.09-5.1%$1.835$2.39$1.621425,715
$1.77+0.01+0.6%$1.87$1.911$1.70759,514
$1.76+0.11+6.7%$1.67$1.97$1.6766,202
$1.65-0.07-4.1%$2.00$2.00$1.6530,904
$1.72+0.04+2.4%$1.70$1.72$1.6358,149
$1.68+0.08+5.0%$1.66$1.71$1.57918,698
$1.60-0.05-3.0%$1.65$1.70$1.6018,516
$1.65-0.04-2.4%$1.65$1.72$1.6520,663
$1.690.000.0%$1.68$1.74$1.62711,445
$1.69-0.09-5.1%$1.72$1.83$1.6926,085
$1.78-0.11-5.8%$1.86$1.95$1.7530,939
$1.89-0.17-8.3%$1.98$2.03$1.8837,786
$2.06-0.095-4.4%$2.18$2.18$2.0510,622
$2.155+0.145+7.2%$2.27$2.27$2.0269,966
$2.01-0.05-2.4%$2.06$2.12$2.0122,514
$2.06-0.04-1.9%$2.08$2.35$2.0498,170
$2.10-0.08-3.7%$2.10$2.28$1.832838,250
$2.18-0.10-4.4%$2.24$2.345$2.0938,032
$2.28-0.06-2.6%$2.35$2.409$2.2727,617
$2.34-0.19-7.5%$2.58$2.58$2.2424,254
$2.53-0.17-6.3%$2.74$2.873$2.40138,123
$2.70-0.17-5.9%$2.90$2.91$2.6578,327
$2.87-0.10-3.4%$2.90$3.00$2.8742,178
$2.97-0.24-7.5%$3.121$3.28$2.8745,694

Splits

4 splits since 2023 · NASDAQ:RNAZ · every price before a split is adjusted for it

DayRatioWhat
1-for-28Consolidation
1-for-33Consolidation
1-for-40Consolidation
1-for-20Consolidation
Ticker
NASDAQ:RNAZ
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All TransCode Therapeutics, Inc. news

TransCode Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
19 in the last 12 months · 113 in all · newest Oct 28, 2026 · oldest 2021
Decks
6 decks · latest September 2026

Where TransCode Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:RNAZ · Home listing · This pageNASDAQUnited StatesUSD
BOATS:RNAZBOATSUnited StatesUSD

Valuation

Price/book 0.6× against a median of 1.2×: 4th lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$15.44M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
0.6×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
1.03

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
TransCode Therapeutics, Inc. · NASDAQ:RNAZUS$20.07MUS$15.44Mn/an/an/a0.6×n/a0.0×1.03
ZYUS Life Sciences Corporation · TSXV:ZYUSUS$20.92MUS$25.65Mn/a98.4×n/an/an/an/a-0.02
Xbrane Biopharma AB · OMXSTO:XBRANEUS$20.88MUS$23.48Mn/a1.9×n/a0.4×−49.0%0.1×n/a
Vivoryon Therapeutics N.V. · EURONEXT:VVYUS$20.48MUS$17.77Mn/an/an/a11.9×n/a0.1×n/a
Evaxion A/S · NASDAQ:EVAXUS$20.30MUS$13.40Mn/a1.8×n/a2.1×−115.1%0.8×0.78
Aardvark Therapeutics, Inc. · NASDAQ:AARDUS$20.20M−US$39.58Mn/an/an/a0.3×n/a0.0×3.28
GenSight Biologics SA · EURONEXT:SIGHTUS$20.19MUS$32.44Mn/a29,573×n/an/an/an/an/a
Adicet Bio, Inc. · NASDAQ:ACETUS$20.03MUS$5.02Mn/an/an/a0.2×n/a0.1×2.02
IGC Pharma, Inc. · AMEX:IGCUS$19.60MUS$19.19Mn/an/an/a3.0×n/a0.0×1.09
Provectus Biopharmaceuticals, Inc. · OTC:PVCTUS$19.12MUS$18.94Mn/an/an/an/an/an/a-0.21
LeonaBio, Inc. · NASDAQ:LONAUS$19.03M−US$12.82Mn/an/an/a1.2×n/a0.0×1.04
Median of the othersUS$20.19MUS$18.35M50.1×1.2×−82.1%0.1×1.04

Forecasts

Analysts' consensus from EODHD, read Nov 15, 2026. Not 6ix's view and not investment advice.

Price target
10.00 USD · Analysts' mean
EPS, year to Dec 2024
-4.76 · 1 analyst
Revenue, year to Dec 2024
300K · 1 analyst

Team and board

Officers

OfficerRole
Philippe CalaisCEO
Elizabeth A. CzerepakCFO, Director
John TattoryInterim CFO
Karrie HilsingerVP of Clinical Operations
Tania Montgomery-HammonVP, Business Development
Michel JanicotConsulting Head of Translational Science
Zdravka MedarovaCofounder/Chief Scientific Officer

Board

DirectorRole
Elizabeth A. CzerepakCFO, Director
Erik MantingDirector
Jack E. StoverDirector
Magda MarquetDirector
Philippe CalaisCEO

Events

QuarterResultsShare move
Q3 2026Nov 16, 2026+6.8%
Q2 2026Aug 14, 2026−9.2%
Q1 2026May 29, 2026+2.7%
Q4 2025Feb 25, 2026+2.7%
Q3 2025Nov 14, 2025+11.8%
Q2 2025Aug 14, 2025−6.9%
Q1 2025Apr 15, 2025 · After close−10.4%
Q4 2024Mar 28, 2025−4.8%
Q3 2024Nov 14, 2024 · After close−2.9%
Q2 2024Aug 14, 2024 · After close+9.7%
All 20 quarters
QuarterResultsShare move
Q1 2024May 15, 2024 · After close+9.7%
Q4 2023Mar 29, 2024+1.3%
Q3 2023Nov 14, 2023 · After close−9.3%
Q2 2023Aug 14, 2023 · After close−1.8%
Q1 2023May 15, 2023 · After close−0.4%
Q4 2022Mar 31, 2023 · After close+3.4%
Q3 2022Nov 14, 2022 · After close+6.7%
Q2 2022Aug 15, 2022 · After close+3.1%
Q1 2022May 16, 2022 · Before open−8.0%
Q4 2021Mar 31, 2022 · After close−1.7%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (September 2026)Investor deck44 slidesSeptember 2026
Investor Presentation (June 2026)Investor deck44 slidesJun 18, 2026
Investor Presentation (December 2025)Investor deck28 slidesDec 18, 2025
Investor Presentation (October 2025)Investor deck35 slidesOct 8, 2025
Investor Presentation (May 2025)Investor deck35 slidesMay 23, 2025
Investor Presentation (October 2024)Investor deck19 slidesOct 28, 2024

Open Decks

Financings

RaiseDate
Strategic investment of non-voting Series B convertible preferred stock
Announced: US$25M · Tungsten Advisors
Dealers: Tungsten Advisors (lead)
Buyers: CK Life Sciences Int'l., (Holdings) Inc. (subsidiary) (223.7337 shares of Series B Preferred Stock for $25 million; approximately 91% fully diluted together with the acquisition)
Use of proceeds: Primarily to advance clinical development of lead microRNA asset TTX-MC138 into a Phase 2 clinical trial
Oct 9, 2025
Registered direct offering of shares of common stock and warrants
Closed: US$10M raised · US$0.98 a share · Warrants at US$0.86 for 60 months · ThinkEquity
Dealers: ThinkEquity (lead)
Use of proceeds: Product development, including clinical trials of TTX-MC138 and IND-enabling studies, plus working capital and general corporate purposes
Mar 25, 2025
Private placement of shares of common stock with Series C and Series D warrants
Update: about US$8M · US$0.377 a share · Warrants at US$0.475 for 60 months · The Benchmark Company, LLC
Dealers: The Benchmark Company, LLC (lead)
Use of proceeds: General corporate purposes and working capital
Feb 25, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$4.00 a share on Jul 8, 2021.

Price
US$4.00 a share
Shares offered
6,250,000 shares of common stock
Offering size
US$25 million
Underwriters' option
Up to 937,500 more shares
Listing
RNAZ on the Nasdaq Capital Market
Underwriter
ThinkEquity
Shares delivered
On or about Jul 13, 2021

Steps

StepWhen
Draft sent to the SEC in confidenceDec 18, 2020
Filed publiclyFeb 26, 2021
Amended 5 timesNewest Jun 2, 2021
Shares registered with an exchangeApr 26, 2021
Declared effective by the SECJul 8, 2021
Final prospectus, with the priceJul 9, 2021

Open IPO · From the cover of the final prospectus (424B4) filed Jul 9, 2021

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue0000000
Cost of revenue114.2K534.9K516.7K98.6K42.5K
Gross profit-114.2K-534.9K-516.7K-98.6K-42.5K
Research and development13.4M9.71M12.3M10.2M2.75M284.5K226.3K82.5K
Selling, general and administrative5.77M5.95M7.15B8.43M3.40M442.1K230.6K301.5K
Operating income-28.0M-15.7M-19.4M-18.6M-6.15M-726.6K-456.9K-384.0K
Depreciation and amortization13.4K90.9K123.5K98.6K42.5K042.5K384.0K
EBITDA-28.0M-15.6M-19.3M-18.5M-6.11M-726.6K-414.4K0
Interest expense6.62K26.8K55.9K32.0K95.1K394.6K157.0K0
Income before tax-34.4M-16.8M-18.5M-17.6M-6.84M-2.34M-607.2K-453.4K
Income tax226.1K00053.1K0156.9K-69.4K
Net income-34.7M-16.8M-18.5M-17.6M-6.84M-2.34M-607.2K-453.4K
Earnings per share, basic-52.59-1,336.63-3,419.01-1,082.79-0.81-0.51-94.77
Earnings per share, diluted-52.59-1,336.63-3,419.01-1,082.79-0.81-0.51

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash and equivalents17.8M5.81M2.77M4.97M20.8M828.0K204.5K213.0K
Short-term investments9.41K93
Receivables3.25M360.2K
Inventory554.3K
Current assets22.0M7.09M4.46M7.38M22.7M831.2K204.5K214.6K
Property, plant and equipment370.7K51.6K120.7K208.6K206.3K
Goodwill25.7M0
Total assets162.4M7.29M5.17M7.59M22.9M1.06M216.7K214.6K
Accounts payable3.12M2.58M2.33M4.12M2.02M369.2K27.3K
Current liabilities3.49M2.77M3.49M4.35M2.53M404.9K62.9K117.7K
Long-term debt2.09M927.8K
Total debt38.3K450.6K2.09M927.8K471.9K
Total liabilities10.5M9.31M3.53M4.35M2.53M4.46M1.31M718.6K
Shareholders' equity10.3M-2.02M1.64M3.24M20.4M-3.41M-1.10M-504.0K
Shares outstanding917.0K36.8K19.0K16.2K12.9M4.64M6.41K192

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash from operations-19.5M-13.3M-18.1M-15.8M-5.27M-493.0K-508.5K-299.6K
Capital spending-6.66K-21.8K-35.6K-100.9K-254.8K-254.8K-254.8K-254.8K
Free cash flow-19.5M-13.4M-18.1M-15.9M-5.52M-493.0K-508.5K-299.6K
Cash from investing-4.44K-21.8K-35.6K-100.9K-251.8K-251.8K-251.8K-251.8K
Cash from financing31.5M16.4M15.9M5.99K25.5M1.12M500.0K512.4K
Dividends paid-1.61B-30.6M
Change in cash12.0M3.04M-2.20M-15.9M20.0M623.5K-8.51K212.9K

Open Financials

Filings

FilingDateTypeFiled with
S-8 · Registration statement for employee plansNov 16, 2026Offer documentSEC
10-Q · Quarterly reportNov 16, 2026Quarterly reportSEC
8-K · Current reportOct 28, 2026Current reportSEC
8-K · Current reportOct 1, 2026Material contractSEC
8-K · Current reportSep 28, 2026Current reportSEC
3 · Initial statement of ownershipSep 21, 2026Insider tradeSEC
4 · Change in ownershipSep 11, 2026Insider tradeSEC
8-K · Current reportSep 11, 2026Management or board changeSEC
10-Q · Quarterly reportAug 14, 2026Quarterly reportSEC
4 · Change in ownershipAug 5, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
3 · Initial statement of ownershipAug 5, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedAug 3, 2026Big-stake noticeSEC
8-K · Current reportAug 3, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeJul 28, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJul 28, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJul 28, 2026Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJul 27, 2026Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJul 23, 2026Big-stake noticeSEC
424B3 · ProspectusJul 20, 2026Offer documentSEC
424B3 · ProspectusJul 20, 2026Offer documentSEC
8-K · Current reportJul 20, 2026Meeting outcomeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJul 17, 2026Big-stake noticeSEC
DEFA14A · Additional proxy materialJul 17, 2026Meeting noticeSEC
8-K · Current reportJul 17, 2026Current reportSEC
8-K · Current reportJul 2, 2026Current reportSEC
8-K · Current reportJun 18, 2026Current reportSEC
8-K · Current reportJun 3, 2026Current reportSEC
ARS · Annual report to shareholdersJun 2, 2026Annual reportSEC
DEF 14A · Proxy statementJun 2, 2026Meeting noticeSEC
8-K · Current reportJun 1, 2026Current reportSEC
DEFA14A · Additional proxy materialMay 26, 2026Meeting noticeSEC
8-K/A · Current report, amendedMay 26, 2026Current reportSEC
8-K · Current reportMay 22, 2026Current reportSEC
EFFECT · Notice that a registration is effectiveMay 20, 2026Other filingsSEC
EFFECT · Notice that a registration is effectiveMay 20, 2026Other filingsSEC
CORRESP · Letter to the SECMay 15, 2026Other filingsSEC
CORRESP · Letter to the SECMay 15, 2026Other filingsSEC
10-Q · Quarterly reportMay 15, 2026Quarterly reportSEC
PRE 14A · Preliminary proxy statementMay 8, 2026Meeting noticeSEC
UPLOAD · Letter from the SECMay 6, 2026Other filingsSEC
UPLOAD · Letter from the SECMay 6, 2026Other filingsSEC
S-1 · Registration statementApr 30, 2026Offer documentSEC
S-3 · Registration statementApr 30, 2026Offer documentSEC
10-K/A · Annual report, amendedApr 30, 2026Annual reportSEC
SCHEDULE 13G · Big-stake noticeApr 20, 2026Big-stake noticeSEC
10-K · Annual reportApr 15, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 7, 2026Meeting noticeSEC
8-K · Current reportApr 7, 2026Material contractSEC
NT 10-K · Late filing noticeMar 31, 2026Explanation requestSEC
DEFA14A · Additional proxy materialMar 3, 2026Meeting noticeSEC
8-K · Current reportMar 3, 2026FinancingSEC
8-K · Current reportFeb 23, 2026Current reportSEC
8-K · Current reportFeb 5, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 7, 2026Big-stake noticeSEC
8-K · Current reportJan 6, 2026Current reportSEC
DEFA14A · Additional proxy materialDec 23, 2025Meeting noticeSEC
8-K/A · Current report, amendedDec 23, 2025Current reportSEC
EFFECT · Notice that a registration is effectiveDec 23, 2025Other filingsSEC
3 · Initial statement of ownershipDec 22, 2025Insider tradeSEC
3 · Initial statement of ownershipDec 22, 2025Insider tradeSEC
8-K · Current reportDec 22, 2025Management or board changeSEC
CORRESP · Letter to the SECDec 18, 2025Other filingsSEC
S-3 · Registration statementDec 12, 2025Offer documentSEC
8-K · Current reportDec 11, 2025Current reportSEC
10-Q · Quarterly reportNov 14, 2025Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 10, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedOct 28, 2025Big-stake noticeSEC
DEFA14A · Additional proxy materialOct 27, 2025Meeting noticeSEC
8-K · Current reportOct 27, 2025Current reportSEC
DEFA14A · Additional proxy materialOct 17, 2025Meeting noticeSEC
8-K/A · Current report, amendedOct 17, 2025Material contractSEC
SCHEDULE 13D · Big-stake noticeOct 16, 2025Big-stake noticeSEC
8-K · Current reportOct 14, 2025Current reportSEC
DEFA14A · Additional proxy materialOct 8, 2025Meeting noticeSEC
8-K/A · Current report, amendedOct 8, 2025Material contractSEC
DEFA14A · Additional proxy materialOct 8, 2025Meeting noticeSEC
8-K · Current reportOct 8, 2025Acquisition or disposalSEC
8-K · Current reportOct 3, 2025Material contractSEC
8-K · Current reportSep 2, 2025Meeting outcomeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 14, 2025Quarterly reportSEC
SCHEDULE 13G · Big-stake noticeAug 14, 2025Big-stake noticeSEC
DEF 14A · Proxy statementJul 15, 2025Meeting noticeSEC
8-K · Current reportJun 13, 2025Current reportSEC
10-Q · Quarterly reportMay 14, 2025Quarterly reportSEC
8-K · Current reportMay 7, 2025Current reportSEC
8-K · Current reportMay 5, 2025Current reportSEC
8-K · Current reportMay 2, 2025Meeting outcomeSEC
10-K/A · Annual report, amendedApr 30, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 21, 2025Meeting noticeSEC
8-K · Current reportApr 21, 2025Meeting outcomeSEC
DEFA14A · Additional proxy materialApr 16, 2025Meeting noticeSEC
10-K · Annual reportApr 15, 2025Annual reportSEC
DEF 14A · Proxy statementApr 11, 2025Meeting noticeSEC
PRE 14A · Preliminary proxy statementApr 2, 2025Meeting noticeSEC
NT 10-K · Late filing noticeMar 31, 2025Explanation requestSEC
8-K · Current reportMar 25, 2025Material contractSEC
424B5 · ProspectusMar 25, 2025Offer documentSEC
SCHEDULE 13D · Big-stake noticeMar 20, 2025Big-stake noticeSEC
8-K · Current reportFeb 25, 2025Meeting outcomeSEC
SCHEDULE 13G · Big-stake noticeFeb 14, 2025Big-stake noticeSEC
DEFA14A · Additional proxy materialFeb 4, 2025Meeting noticeSEC
8-K · Current reportFeb 4, 2025Meeting outcomeSEC
SCHEDULE 13G · Big-stake noticeJan 3, 2025Big-stake noticeSEC
DEF 14A · Proxy statementDec 30, 2024Meeting noticeSEC
8-K · Current reportDec 20, 2024Current reportSEC
PRE 14A · Preliminary proxy statementDec 19, 2024Meeting noticeSEC
EFFECT · Notice that a registration is effectiveDec 18, 2024Other filingsSEC
CORRESP · Letter to the SECDec 13, 2024Other filingsSEC
UPLOAD · Letter from the SECDec 13, 2024Other filingsSEC
DDec 12, 2024Other filingsSEC
S-1 · Registration statementDec 6, 2024Offer documentSEC
8-K · Current reportDec 2, 2024Material contractSEC
8-K · Current reportNov 29, 2024Current reportSEC
8-K · Current reportNov 25, 2024Meeting outcomeSEC
10-Q · Quarterly reportNov 14, 2024Quarterly reportSEC
DEFA14A · Additional proxy materialNov 13, 2024Meeting noticeSEC
SC 13G/A · Big-stake notice, amendedNov 6, 2024Big-stake noticeSEC
DEFA14A · Additional proxy materialNov 6, 2024Meeting noticeSEC
8-K · Current reportNov 6, 2024Current reportSEC
DEF 14A · Proxy statementOct 28, 2024Meeting noticeSEC
PRE 14A · Preliminary proxy statementOct 15, 2024Meeting noticeSEC
8-K · Current reportSep 27, 2024Current reportSEC
8-K · Current reportAug 28, 2024Current reportSEC
8-K · Current reportAug 16, 2024Current reportSEC
10-Q · Quarterly reportAug 14, 2024Quarterly reportSEC
SC 13G · Big-stake noticeJul 26, 2024Big-stake noticeSEC
8-K · Current reportJul 24, 2024Material contractSEC
424B5 · ProspectusJul 24, 2024Offer documentSEC
424B5 · ProspectusJul 22, 2024Offer documentSEC
SC 13D · Big-stake noticeJun 21, 2024Big-stake noticeSEC
4 · Change in ownershipJun 18, 2024Insider tradeSEC
4 · Change in ownershipJun 18, 2024Insider tradeSEC
4 · Change in ownershipJun 18, 2024Insider tradeSEC
4 · Change in ownershipJun 18, 2024Insider tradeSEC
8-K/A · Current report, amendedJun 14, 2024Meeting outcomeSEC
8-K · Current reportJun 13, 2024Meeting outcomeSEC
DEFA14A · Additional proxy materialJun 10, 2024Meeting noticeSEC
DEFA14A · Additional proxy materialJun 7, 2024Meeting noticeSEC
8-K · Current reportJun 7, 2024Current reportSEC
DEFR14AMay 20, 2024Meeting noticeSEC
8-K · Current reportMay 15, 2024Current reportSEC
10-Q · Quarterly reportMay 15, 2024Quarterly reportSEC
DEFA14A · Additional proxy materialMay 13, 2024Meeting noticeSEC
PRE 14A · Preliminary proxy statementMay 10, 2024Meeting noticeSEC
8-K · Current reportMay 10, 2024Current reportSEC
ARS · Annual report to shareholdersApr 29, 2024Annual reportSEC
DEF 14A · Proxy statementApr 29, 2024Meeting noticeSEC
8-K · Current reportApr 23, 2024Current reportSEC
8-K · Current reportApr 5, 2024ResultsSEC
10-K · Annual reportApr 1, 2024Annual reportSEC
SC 13G/A · Big-stake notice, amendedFeb 15, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 13, 2024Big-stake noticeSEC
8-K · Current reportJan 31, 2024Current reportSEC
8-K · Current reportJan 22, 2024Material contractSEC
424B4 · ProspectusJan 19, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveJan 19, 2024Other filingsSEC
S-1/A · Registration statement, amendedJan 18, 2024Offer documentSEC
CORRESP · Letter to the SECJan 17, 2024Other filingsSEC
CORRESP · Letter to the SECJan 17, 2024Other filingsSEC
S-1/A · Registration statement, amendedJan 17, 2024Offer documentSEC
UPLOAD · Letter from the SECJan 16, 2024Other filingsSEC
8-K · Current reportJan 16, 2024ResultsSEC
S-1 · Registration statementJan 11, 2024Offer documentSEC
8-K · Current reportJan 8, 2024Meeting outcomeSEC
DEFA14A · Additional proxy materialJan 4, 2024Meeting noticeSEC
DEF 14A · Proxy statementDec 18, 2023Meeting noticeSEC
PRE 14A · Preliminary proxy statementDec 8, 2023Meeting noticeSEC
8-K · Current reportDec 8, 2023Current reportSEC
SC 13G · Big-stake noticeDec 7, 2023Big-stake noticeSEC
8-K · Current reportDec 4, 2023Material contractSEC
424B5 · ProspectusDec 1, 2023Offer documentSEC
10-Q · Quarterly reportNov 14, 2023Quarterly reportSEC
8-K · Current reportNov 14, 2023ResultsSEC
8-K · Current reportNov 9, 2023Current reportSEC
8-K · Current reportOct 27, 2023Current reportSEC
424B5 · ProspectusOct 26, 2023Offer documentSEC
8-K · Current reportOct 24, 2023Current reportSEC
SC 13D/A · Big-stake notice, amendedOct 10, 2023Big-stake noticeSEC
4 · Change in ownershipOct 2, 2023Insider tradeSEC
4 · Change in ownershipOct 2, 2023Insider tradeSEC
8-K · Current reportSep 28, 2023Material contractSEC
424B4 · ProspectusSep 27, 2023Offer documentSEC
SC 13G · Big-stake noticeSep 26, 2023Big-stake noticeSEC
EFFECT · Notice that a registration is effectiveSep 26, 2023Other filingsSEC
CORRESP · Letter to the SECSep 25, 2023Other filingsSEC
CORRESP · Letter to the SECSep 25, 2023Other filingsSEC
CORRESP · Letter to the SECSep 25, 2023Other filingsSEC
CORRESP · Letter to the SECSep 25, 2023Other filingsSEC
CORRESP · Letter to the SECSep 22, 2023Other filingsSEC
CORRESP · Letter to the SECSep 22, 2023Other filingsSEC
CORRESP · Letter to the SECSep 22, 2023Other filingsSEC
S-1/A · Registration statement, amendedSep 22, 2023Offer documentSEC
CORRESP · Letter to the SECSep 15, 2023Other filingsSEC
CORRESP · Letter to the SECSep 15, 2023Other filingsSEC
S-1/A · Registration statement, amendedSep 8, 2023Offer documentSEC
UPLOAD · Letter from the SECAug 31, 2023Other filingsSEC
S-1 · Registration statementAug 29, 2023Offer documentSEC
8-K · Current reportAug 24, 2023Current reportSEC

This page holds 200 of 326 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from TransCode Therapeutics, Inc.’s releases · as of Nov 12, 2026

Common shares
17,303,883
Fully diluted
17,303,883

Fully diluted

LineSharesAs of
Common shares17,303,883Nov 12, 2026

Warrants and options

Lot
Warrants · US$0.86 · expire about Mar 2030

Share count over time

CountShares
Nov 12, 202617,303,883

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Yorkville Advisors Global, LP75,7860.44%US$127KSep 30, 2026
Citadel10,2070.06%US$17,148Sep 30, 2026
Vanguard9,5270.06%US$16,006Sep 30, 2026
UBS2,6500.02%US$4,452Sep 30, 2026
Tower Research Capital LLC (TRC)1,7460.01%US$2,934Sep 30, 2026
Osaic Holdings, Inc.270<0.01%US$453Sep 30, 2026
Robinhood Markets, Inc.102<0.01%US$168Sep 30, 2026
Wells Fargo55<0.01%US$92Sep 30, 2026
SBI Securities Co., Ltd.12<0.01%US$20Sep 30, 2026
Fidelity11<0.01%US$18Sep 30, 2026
All 12 holders
HolderSharesOf the companyValueAs of
IFP Advisors, Inc8<0.01%US$13Sep 30, 2026
Northwestern Mutual Wealth Management Co1<0.01%US$2Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
Fidelity Extended Market Index Fund8,4920.05%US$43,649May 31, 2026
Vanguard Extended Market Index Fund6,5450.04%US$40,644Jun 30, 2026
Fidelity Series Total Market Index Fund1,180<0.01%US$6,065May 31, 2026
Fidelity Total Market Index Fund510<0.01%US$2,621May 31, 2026

Big stakes

StakeStakeSharesDateFiling
CK Life Sciences Int'l., (Holdings) Inc.83.90%14.1MAug 3, 2026Schedule 13D
Unleash Immuno Oncolytics, Inc.9.94%300KJul 23, 2026Schedule 13G
YA II PN, Ltd.9.90%102KApr 15, 2026Schedule 13G
Elena Rosa Braci6.17%186KJul 23, 2026Schedule 13G
Daniel Eduardo Katzman5.16%156KJul 23, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Jack E Stover
Other companies: Profusa, Inc. (Chief Executive Officer · Since at least Dec 20, 2021); Traws Pharma, Inc. (Director · Since at least May 18, 2016); PharmaCyte Biotech, Inc. (Director · Aug 15, 2022 – Aug 15, 2022 · Past); Antares Pharma Inc (President and CEO, Director · Jan 25, 2006 – May 14, 2008 · Past); Interpace Biosciences, Inc. (President and CEO, Director · Aug 3, 2005 – Mar 12, 2020 · Past)
Director · Since at least Dec 19, 2025
Magda Marquet
Other companies: First Tracks Biotherapeutics, Inc. (Director · Since at least Apr 1, 2026); Immix Biopharma, Inc. (Independent Director · Since at least Dec 15, 2021); AnaptysBio, Inc. (Director · Since at least Jan 18, 2021); Arcturus Therapeutics Holdings Inc. (Director · Since at least Jan 1, 2019); Pfenex Inc (Director · Feb 28, 2019 – Oct 1, 2020 · Past)
Director · Since at least Jul 8, 2021
Elizabeth Czerepak
Other companies: Delcath Systems, Inc. (DIRECTOR · Since at least Feb 14, 2020); Scilex Holding Company (See Remarks · Nov 10, 2022 – Jan 17, 2023 · Past); Sorrento Therapeutics, Inc. (EVP & Chief Financial Officer · Nov 15, 2021 – May 18, 2022 · Past); Spectrum Pharmaceuticals Inc (Director · Jun 19, 2019 – Jun 18, 2020 · Past)
CFO, Director · Since at least Oct 6, 2025
Jack E. Stover
Other companies: Profusa, Inc. (Director · Since at least Aug 20, 2026)
Director · Since at least Dec 22, 2025
John Tattory
Other companies: Windtree Therapeutics, Inc. (Interim CFO · Jul 28, 2016 – Jan 27, 2023 · Past)
Interim CFO · Since at least Sep 10, 2026
Philippe Calais
Other companies: CohBar Inc (Director · Jun 6, 2018 – May 31, 2019 · Past)
CEO · Since at least Jul 8, 2021
Anna MooreChair of Scientific Advisory Board · Since at least Apr 27, 2026
Erik MantingDirector · Since at least Jul 8, 2021
Karrie HilsingerVP of Clinical Operations · Since at least Nov 4, 2026
Michel JanicotConsulting Head of Translational Science · Since at least Nov 17, 2025
All 14 people
PersonSeat
Robert Michael DudleyChief Executive Officer, Director · Jul 8, 2021 – Sep 28, 2023 · Past
Tania Montgomery-HammonVP, Business Development · Since at least Oct 13, 2026
Thomas A FitzgeraldChief Financial Officer, Director · Since at least Jul 8, 2021
Zdravka MedarovaCofounder/Chief Scientific Officer · Since at least Feb 1, 2022

Open People

Log in to ask 6ix AI your own questions about TransCode Therapeutics, Inc.